Release Details

SOUTH PLAINFIELD, N.J., Feb. 3, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will host a conference call on Thursday, February 6, 2020, at 8:00 am ET highlighting data on risdiplam in type 2/3 spinal muscular atrophy patients from part 2 of the SUNFISH trial presented at the 2^nd International Scientific Congress on Spinal Muscular Atrophy, (5 - 7 Feb) in Evry, France. PTC management will be joined on the call by Dr. Basil Darras, Associate Neurologist in-Chief and Director of the Spinal Muscular Atrophy Clinical Research Program at Boston Children's Hospital.

The call can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 7757508. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at www.ptcbio.com. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for 30 days following the call. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection. PTC's current Investor Presentation is available at the same website location.

About PTC Therapeutics, Inc.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.

View original content to download multimedia:http://www.prnewswire.com/news-releases/ptc-therapeutics-to-host-a-conference-call-to-review-part-2-of-the-sunfish-clinical-trial-data-at-the-sma-europe-conference-300997533.html

SOURCE PTC Therapeutics, Inc.